Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia
Conferences
Malek, SN; Ouillette, P; Kujawski, L; Shangary, S; Talpaz, M; Kaminski, M; Erba, H; Shedden, K; Wang, S
Published in: BLOOD
November 16, 2007
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2007
Volume
110
Issue
11
Start / End Page
73A / 73A
Location
Atlanta, GA
Publisher
AMER SOC HEMATOLOGY
Conference Name
49th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
Citation
APA
Chicago
ICMJE
MLA
NLM
Malek, S. N., Ouillette, P., Kujawski, L., Shangary, S., Talpaz, M., Kaminski, M., … Wang, S. (2007). Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. In BLOOD (Vol. 110, pp. 73A-73A). Atlanta, GA: AMER SOC HEMATOLOGY.
Malek, Sami N., Peter Ouillette, Lisa Kujawski, Sanjeev Shangary, Moshe Talpaz, Mark Kaminski, Harry Erba, Kerby Shedden, and Shaomeng Wang. “Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.” In BLOOD, 110:73A-73A. AMER SOC HEMATOLOGY, 2007.
Malek SN, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M, et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. In: BLOOD. AMER SOC HEMATOLOGY; 2007. p. 73A-73A.
Malek, Sami N., et al. “Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.” BLOOD, vol. 110, no. 11, AMER SOC HEMATOLOGY, 2007, pp. 73A-73A.
Malek SN, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M, Erba H, Shedden K, Wang S. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. BLOOD. AMER SOC HEMATOLOGY; 2007. p. 73A-73A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2007
Volume
110
Issue
11
Start / End Page
73A / 73A
Location
Atlanta, GA
Publisher
AMER SOC HEMATOLOGY
Conference Name
49th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology